Abstract 1010P
Background
B7H7, a novel immune checkpoint, is a promising target in solid tumors due to its overexpression and correlation with poor prognosis. HBM1020 is a first-in-class anti-B7H7 antibody designed to augment T cell anti-tumor response.
Methods
This objective of this phase 1 study is to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HBM1020 in patients (pts) with advanced solid tumors. In Part 1 (dose escalation), HBM1020 was administered at dose levels between 0.3mg/kg and 30mg/kg every 3 weeks (Q3W) by intravenous infusion. Enrollment is ongoing in Part 2 (dose expansion).
Results
As of 01-April-2024, 17 pts with have received HBM1020 from 0.3mg/kg to 30 mg/kg Q3W. Median age was 62 years (34-80). All pts completed dose limiting toxicity (DLT) observation periods (21 days) and no DLT events were observed and MTD has not yet been reached. A total of 6 (35.3%) pts had a treatment related adverse event (TRAE) and all TRAEs were Grade 1-2. Eleven (64.7%) pts had reported serious adverse events (SAEs) and all SAEs were deemed unrelated to study treatment by both investigator and study sponsor. Nine (9) pts had post baseline tumor evaluation, and 6 out of 9 (66.7%) pts had stable disease (SD) as best response (including 1 pt with SD, tumor shrinkage of 25%). PK analysis of HBM1020 demonstrated a typical IgG behavior with elimination half-life of ∼two weeks in the dose range of 3 to 20 mg/kg. Drug exposure increased in a nearly dose-proportional manner. The expression of B7H7 was assessed by validated immunohistochemistry (IHC) assay for patients with available archived samples.
Conclusions
HBM1020, as a first-in-class anti-B7H7 antibody, demonstrated promising safety and tolerability profiles in patients with advanced solid tumors. Further studies are warranted to explore the therapeutic potential of HBM1020 in solid tumors.
Clinical trial identification
NCT05824663.
Editorial acknowledgement
Legal entity responsible for the study
Harbour Biomed US.
Funding
Harbour Biomed US.
Disclosure
X. Tao: Financial Interests, Personal, Full or part-time Employment: Harbour Biomed Ltd; Financial Interests, Personal, Stocks/Shares: Harbour Biomed Ltd. All authors have declared no conflicts of interest.
Resources from the same session
907P - Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Denis Soulieres
Session: Poster session 03
909P - Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial
Presenter: Alix Marhic
Session: Poster session 03
911P - Association of genomic landscape and plasma protein dynamic changes with clinical outcome in patients with R/M HNSCC treated with pembrolizumab with nab-paclitaxel and platinum
Presenter: Xinrui Chen
Session: Poster session 03
912P - Selection of personalized salvage treatments in advanced refractory head and neck squamous cell carcinomas via multi-omics tumor profiling
Presenter: Ramin Ajami
Session: Poster session 03
913P - Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer
Presenter: Juan Carlos Redondo González
Session: Poster session 03
914P - The landscape of somatic copy number alterations of head and neck squamous cell carcinoma across different anatomic sites
Presenter: Juan Carlos Redondo González
Session: Poster session 03
915P - Longer OS and RFS for CD3high/PD-L1+ head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Simon Laban
Session: Poster session 03
916P - Deep spatial profiling of head and neck squamous cell carcinoma offers insights into the tumor microenvironment of hpv-stratified patients
Presenter: Abhishek Aggarwal
Session: Poster session 03